Amvuttra Dosage
Generic name: VUTRISIRAN SODIUM 25mg in 0.5mL
Dosage form: injection
Drug class: Miscellaneous metabolic agents
Medically reviewed by Drugs.com. Last updated on Mar 25, 2025.
Recommended Dosage
The recommended dosage of AMVUTTRA is 25 mg administered by subcutaneous injection once every 3 months.
Administration Instructions
AMVUTTRA is for subcutaneous use only and should be administered by a healthcare professional.
Preparation and Administration
|
|
|
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
|
More about Amvuttra (vutrisiran)
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Drug images
- Side effects
- During pregnancy
- FDA approval history
- Drug class: miscellaneous metabolic agents
- En español
Patient resources
Professional resources
Related treatment guides
See also:
Vyndamax
Vyndamax may be given to reduce death or hospitalization caused by heart problems in adults with ...
Attruby
Attruby (acoramidis) tablets are used to treat cardiomyopathy of wild-type or hereditary ...
Wainua
Wainua (eplontersen) is used to treat polyneuropathy of hereditary transthyretin-mediated ...
Tegsedi
Tegsedi (inotersen) is an RNA-targeting treatment that may be used to reduce the symptoms of ...
Vyndaqel
Vyndaqel (tafamidis meglumine) is a transthyretin stabilizer that may be given to reduce death or ...
Onpattro
Onpattro is used to treat polyneuropathy in adults with hereditary transthyretin-mediated ...
Eplontersen
Eplontersen (Wainua) is used to treat polyneuropathy of hereditary transthyretin-mediated ...
Patisiran
Patisiran (brand name Onpattro) is an injectable treatment for polyneuropathy caused by hereditary ...
Acoramidis
Acoramidis systemic is used for cardiomyopathy of transthyretin-mediated amyloidosis
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.